Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1286


Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up.

Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini GF.

Circulation. 2009 Jan 20;119(2):237-42. doi: 10.1161/CIRCULATIONAHA.108.812636. Epub 2008 Dec 31.


High on-treatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting.

Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini GF.

Thromb Haemost. 2010 Aug;104(2):279-86. doi: 10.1160/TH10-01-0007. Epub 2010 May 27.


Thrombotic events in high risk patients are predicted by evaluating different pathways of platelet function.

Gori AM, Marcucci R, Paniccia R, Giusti B, Fedi S, Antonucci E, Buonamici P, Antoniucci D, Gensini GF, Abbate R.

Thromb Haemost. 2008 Dec;100(6):1136-45.


Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients.

Cuisset T, Frere C, Quilici J, Gaborit B, Castelli C, Poyet R, Bali L, Morange PE, Alessi MC, Bonnet JL.

Am J Cardiol. 2009 Oct 15;104(8):1078-82. doi: 10.1016/j.amjcard.2009.06.007.


Impaired endogenous thrombolysis in acute coronary syndrome patients predicts cardiovascular death and nonfatal myocardial infarction.

Saraf S, Christopoulos C, Salha IB, Stott DJ, Gorog DA.

J Am Coll Cardiol. 2010 May 11;55(19):2107-15. doi: 10.1016/j.jacc.2010.01.033.


Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent.

Wang ZJ, Zhou YJ, Liu YY, Yu M, Shi DM, Zhao YX, Guo YH, Cheng WJ, Jia de A, Cao Z, Nie B, Ge HL, Yang SW, Yan ZX.

Thromb Res. 2009 May;124(1):46-51. doi: 10.1016/j.thromres.2008.10.007. Epub 2008 Nov 28.


High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease.

Migliorini A, Valenti R, Marcucci R, Parodi G, Giuliani G, Buonamici P, Cerisano G, Carrabba N, Gensini GF, Abbate R, Antoniucci D.

Circulation. 2009 Dec 1;120(22):2214-21. doi: 10.1161/CIRCULATIONAHA.109.883454. Epub 2009 Nov 16.


Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?

Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA.

J Am Coll Cardiol. 2007 Feb 13;49(6):657-66. Epub 2007 Jan 26.


Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis.

Aradi D, Komócsi A, Vorobcsuk A, Rideg O, Tokés-Füzesi M, Magyarlaki T, Horváth IG, Serebruany VL.

Am Heart J. 2010 Sep;160(3):543-51. doi: 10.1016/j.ahj.2010.06.004. Review.


Preprocedural high-sensitivity C-reactive protein predicts death or myocardial infarction but not target vessel revascularization or stent thrombosis after percutaneous coronary intervention.

Delhaye C, Sudre A, Lemesle G, Maréchaux S, Broucqsault D, Hennache B, Bauters C, Lablanche JM.

Cardiovasc Revasc Med. 2009 Jul-Sep;10(3):144-50. doi: 10.1016/j.carrev.2009.01.005.


High post-clopidogrel platelet reactivity assessed by a point-of-care assay predicts long-term clinical outcomes in patients with ST-segment elevation myocardial infarction who underwent primary coronary stenting.

Jin HY, Yang TH, Kim DI, Chung SR, Seo JS, Jang JS, Kim DK, Kim DK, Kim KH, Seol SH, Nam CW, Hur SH, Kim W, Park JS, Kim YJ, Kim DS.

Int J Cardiol. 2013 Sep 1;167(5):1877-81. doi: 10.1016/j.ijcard.2012.04.154. Epub 2012 Jun 9.


Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention.

Buch AN, Singh S, Roy P, Javaid A, Smith KA, George CE, Pichard AD, Satler LF, Kent KM, Suddath WO, Waksman R.

Am J Cardiol. 2007 Jun 1;99(11):1518-22. Epub 2007 Apr 13.


Comparison of coronary artery stenting outcomes in the eras before and after the introduction of drug-eluting stents.

Hannan EL, Racz M, Holmes DR, Walford G, Sharma S, Katz S, Jones RH, King SB 3rd.

Circulation. 2008 Apr 22;117(16):2071-8. doi: 10.1161/CIRCULATIONAHA.107.725531. Epub 2008 Apr 7.


Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease.

Angiolillo DJ, Bernardo E, Sabaté M, Jimenez-Quevedo P, Costa MA, Palazuelos J, Hernández-Antolin R, Moreno R, Escaned J, Alfonso F, Bañuelos C, Guzman LA, Bass TA, Macaya C, Fernandez-Ortiz A.

J Am Coll Cardiol. 2007 Oct 16;50(16):1541-7. Epub 2007 Oct 1.


Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting.

Sibbing D, Morath T, Braun S, Stegherr J, Mehilli J, Vogt W, Schömig A, Kastrati A, von Beckerath N.

Thromb Haemost. 2010 Jan;103(1):151-9. doi: 10.1160/TH09-05-0284. Epub 2009 Oct 26.


Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.

Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, Tanguay JF, Cannon CP, Topol EJ.

Circulation. 2011 Sep 6;124(10):1132-7. doi: 10.1161/CIRCULATIONAHA.111.029165. Epub 2011 Aug 29.

Supplemental Content

Support Center